These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 22644934)

  • 1. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
    Krishnan B; Torti FM; Gallagher PE; Tallant EA
    Prostate; 2013 Jan; 73(1):60-70. PubMed ID: 22644934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.
    Krishnan B; Smith TL; Dubey P; Zapadka ME; Torti FM; Willingham MC; Tallant EA; Gallagher PE
    Prostate; 2013 Jan; 73(1):71-82. PubMed ID: 22644942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts.
    Pei N; Wan R; Chen X; Li A; Zhang Y; Li J; Du H; Chen B; Wei W; Qi Y; Zhang Y; Katovich MJ; Sumners C; Zheng H; Li H
    Mol Cancer Ther; 2016 Jan; 15(1):37-47. PubMed ID: 26671566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor.
    Soto-Pantoja DR; Menon J; Gallagher PE; Tallant EA
    Mol Cancer Ther; 2009 Jun; 8(6):1676-83. PubMed ID: 19509262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.
    Menon J; Soto-Pantoja DR; Callahan MF; Cline JM; Ferrario CM; Tallant EA; Gallagher PE
    Cancer Res; 2007 Mar; 67(6):2809-15. PubMed ID: 17363603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
    Zins K; Kovatchki D; Lucas T; Abraham D
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
    Taylor AP; Osorio L; Craig R; Raleigh JA; Ying Z; Goldenberg DM; Blumenthal RD
    Clin Cancer Res; 2002 Apr; 8(4):1213-22. PubMed ID: 11948135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.
    Tesan T; Gustavsson H; Welén K; Damber JE
    BJU Int; 2008 Sep; 102(8):1034-9. PubMed ID: 18489523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence.
    Taylor AP; Rodriguez M; Adams K; Goldenberg DM; Blumenthal RD
    Int J Cancer; 2003 Jun; 105(2):158-64. PubMed ID: 12673673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placental growth factor upregulation is a host response to antiangiogenic therapy.
    Bagley RG; Ren Y; Weber W; Yao M; Kurtzberg L; Pinckney J; Bangari D; Nguyen C; Brondyk W; Kaplan J; Teicher BA
    Clin Cancer Res; 2011 Mar; 17(5):976-88. PubMed ID: 21343374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human choriocarcinomas: placental growth factor-dependent preclinical tumor models.
    Bagley RG; Ren Y; Kurtzberg L; Weber W; Bangari D; Brondyk W; Teicher BA
    Int J Oncol; 2012 Feb; 40(2):479-86. PubMed ID: 22075622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Montico F; Kido LA; Hetzl AC; Cagnon VH
    Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.
    Wu Y; Hooper AT; Zhong Z; Witte L; Bohlen P; Rafii S; Hicklin DJ
    Int J Cancer; 2006 Oct; 119(7):1519-29. PubMed ID: 16671089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.
    Balbay MD; Pettaway CA; Kuniyasu H; Inoue K; Ramirez E; Li E; Fidler IJ; Dinney CP
    Clin Cancer Res; 1999 Apr; 5(4):783-9. PubMed ID: 10213213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
    Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
    Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II and angiotensin-(1-7) decrease sFlt1 release in normal but not preeclamptic chorionic villi: an in vitro study.
    Anton L; Merrill DC; Neves LA; Gruver C; Moorefield C; Brosnihan KB
    Reprod Biol Endocrinol; 2010 Nov; 8():135. PubMed ID: 21050477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.